Journal: Oxidative Medicine and Cellular Longevity
Article Title: Irisin Ameliorates Intervertebral Disc Degeneration by Activating LATS/YAP/CTGF Signaling
doi: 10.1155/2022/9684062
Figure Lengend Snippet: Decreased expression of FNDC5 in degenerative human NP tissue. (a, b) IHC staining assay of ACAN, COL2A1, ADAMTS4, and TNF- α in control and degenerative human nucleus pulposus tissues. (c) The protein expression levels of COL2A1, ADAMTS4, and TNF- α were detected using western blotting in control and degenerative human NP tissues. (d) The quantitative analysis of the protein bands in (c) using ImageJ software. (e) The protein expression levels of FNDC5 were detected by western blot in the control and degenerative groups. (f) The quantitative analysis of the protein bands in (e) using ImageJ software. The scale bar of images in (a) and (b) was shown (magnification: ×200, scale bar: 100 μ m; magnification: ×400, scale bar: 50 μ m). ∗ P < 0.05, ∗∗ P < 0.01.
Article Snippet: Antibodies against collagen type II (COL2A1), a disintegrin-like and metalloprotease with thrombospondin type-1 motif 4 (ADAMTS4), tumor necrosis factor-alpha (TNF- α ), and a disintegrin-like and metalloprotease with thrombospondin type-1 motif 5 (ADAMTS5) were purchased from Abcam Inc. Antibodies against matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 13 (MMP13), connective tissue growth factor (CTGF), and Hippo signaling relative proteins (LATS1, LATS2, YAP, and phosphor-YAP) and goat anti-rabbit and anti-mouse IgG secondary antibodies were purchased from Cell Signaling Technology Inc. Antibodies against GAPDH and β -tubulin were purchased from Proteintech Group Inc. Antibody against fibronectin type III domain-containing protein 5 (FNDC5) was purchased from Bioss Inc. An irisin reagent was purchased from Novoprotein, and a verteporfin reagent was purchased from MedChemExpress, while a human TNF-alpha reagent was from R&D Systems.
Techniques: Expressing, Immunohistochemistry, Western Blot, Software